Type 1 diabetes
Conditions
Interventions
Until December 2014. The basal insulin changes to insulin glargine or insulin degludec. Set to the same dose of the basal insulin before treatment dose of basal insulin. The subcutaneous injection onc
Sponsors
Toho University School of Medicine, Division of diabetes, metabolism and endocrinology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Type1 diabtes patients who had diagnosed 12 months ago. (2)Patients medicated basal-bolus therapy for more than 12 month (3) Adalts who are 20 years or older (4) Patients who can understand consent brief and other explanation documents having the ability of the agreement about participation in this examination
Exclusion criteria
Exclusion criteria: (1) Type 2 diabetes mellitus patients (2) Patients with severe liver disease (3) Patients with severe renal disease (4) Patients who had myocardial infarction within 3 months, or obvious heart failure case (5) Patients with severe pancreas disease (6) Patients having a cancer (7) Patients with hemoglobin (Hb) less than 11 g/dL (8) Patients that the number of the platelets is less than 100,000 /mm3 (9) Patients with high diabetic neuropathy (10) Patients having a proliferative retinopathy (11) Patients with a serious infectious disease or a serious injury (12) Patients with bowel disease or ileus factors (13) Chronic enteropathy patients with the digestion and absorption abnormality (14) Excessive common custom drinker (15) A pregnant woman or the woman who may be pregnant (16) Patients who was infected with hepatitis B virus or hepatitis C virus (17) In addition, the patient who judged inappropriate by an attendant physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Daily glucose fluctuation (MAGE,SD), incidence of hypoglycemia, change of QOL,change of HbA1c | — |
Countries
Japan
Contacts
Public ContactRyo Iga
Toho University School of Medicine Division of diabetes, metabolism and endocrinology
Outcome results
None listed